Isomorphic inks deals with Eli Lilly and Novartis for drug discovery

January 7, 2024

, By Team SNFYI

Artificial Intelligence Tech

Share via:

Isomorphic Labs, the London-based, drug discovery-focused spin-out of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical giants, Eli Lilly and Novartis, to apply AI to discover new medications to treat diseases. The deals have a combined value of around $3 billion. Isomorphic will receive $45 million upfront […]

© 2023 TechCrunch. All rights reserved. For personal use only.

Isomorphic Labs, the London-based, drug discovery-focused spin-out of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical giants, Eli Lilly and Novartis, to apply AI to discover new medications to treat diseases. The deals have a combined value of around $3 billion. Isomorphic will receive $45 million upfront
© 2023 TechCrunch. All rights reserved. For personal use only.

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Previous News

Tulsa’s tech scene remains resilient amid state’s anti-DEI efforts

Next News

Carta, the cap table management outfit, is accused of unethical tactics by a prominent startup

Popular

More Like this

Isomorphic inks deals with Eli Lilly and Novartis for drug discovery

January 7, 2024

, By Team SNFYI

Artificial Intelligence Tech

Isomorphic Labs, the London-based, drug discovery-focused spin-out of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical giants, Eli Lilly and Novartis, to apply AI to discover new medications to treat diseases. The deals have a combined value of around $3 billion. Isomorphic will receive $45 million upfront […]

© 2023 TechCrunch. All rights reserved. For personal use only.

Isomorphic Labs, the London-based, drug discovery-focused spin-out of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical giants, Eli Lilly and Novartis, to apply AI to discover new medications to treat diseases. The deals have a combined value of around $3 billion. Isomorphic will receive $45 million upfront
© 2023 TechCrunch. All rights reserved. For personal use only.

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

Previous News

Tulsa’s tech scene remains resilient amid state’s anti-DEI efforts

Next News

Carta, the cap table management outfit, is accused of unethical tactics by a prominent startup

More like this

Popular

Upcoming Events

GdfFD GFD GFD GFD GFD GFD GFD